Elotuzumab Brand Name– Empliciti
What is Elotuzumab
Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) protein, which is present on myeloma cells and natural killer cells.
It is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies or in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
Severe and fatal infection has been reported with elotuzumab therapy; monitor patients and treat infection promptly.
Indications
- multiple myeloma
For the treatment of multiple myeloma
NOTE: The FDA has designated elotuzumab as an orphan drug for the treatment of multiple myeloma.
for the treatment of multiple myeloma in patients who have received 1 to 3 prior therapies, in combination with lenalidomide and dexamethasone
Side Effects
- anemia
- anorexia
- antibody formation
- asthenia
- bone pain
- bradycardia
- cataracts
- chest pain (unspecified)
- chills
- constipation
- cough
- diarrhea
- dyspnea
- elevated hepatic enzymes
- fatigue
- fever
- headache
- hepatotoxicity
- hyperbilirubinemia
- hyperglycemia
- hyperkalemia
- hypertension
- hypoalbuminemia
- hypocalcemia
- hypoesthesia
- hyponatremia
- hypotension
- infection
- influenza
- infusion-related reactions
- leukopenia
- lymphopenia
- metabolic acidosis
- muscle cramps
- new primary malignancy
- night sweats
- peripheral edema
- peripheral neuropathy
- pharyngitis
- pulmonary embolism
- renal failure (unspecified)
- thrombocytopenia
- vomiting
- weight loss
Monitoring Parameters
- LFTs
Contraindications
- breast-feeding
- hepatic disease
- hepatotoxicity
- infection
- infusion-related reactions
- laboratory test interference
- new primary malignancy
- pregnancy
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD